ArticleOpen forum infectious diseases2023
Increased Myocardial Infarction Risk Following Herpes Zoster Infection.
Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Efficacy and Effectiveness of the Recombinant Zoster Vaccine Against Herpes Zoster, Herpes Zoster Ophthalmicus, Postherpetic Neuralgia and Dementia: A Systematic Review and Meta-Analysis.Reviews in medical virology · 2026Pooled it
- Viral Infections and Risk of Cardiovascular Disease: Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2025Pooled it
- Bibliometric analysis and visualization mapping of herpes zoster vaccine publications from 1999 to 2024.Frontiers in medicine · 2025Pooled it
- Herpes Zoster Vaccination as Cardiovascular Prevention in Adults with Heart Disease.Cardiovascular drugs and therapy · 2026Review
- Adjuvanted Recombinant Zoster Vaccine is Effective Against Herpes Zoster Ophthalmicus, and is Associated With Lower Risk of Acute Myocardial Infarction and Stroke in Adults Aged ≥50 Years.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Herpes Zoster Reactivation in Patients with Coronary Artery Disease.Infection & chemotherapy · 2025Article
- Article
- Article
- Vaccination in Patients with Cardiovascular Disease: A Case-Based Approach and Contemporary Review.CJC open · 2025Review
- Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster.Arthritis research & therapy · 2025Observational
- [Vaccination and cardiovascular diseases].Herz · 2025Review
- Evaluating the Immunogenicity, Efficacy, and Effectiveness of Recombinant Zoster Vaccine for Global Public Health Policy.Vaccines · 2025Review
- Saudi Heart Association Position Statement on Adult Vaccinations for Patients With Cardiovascular Diseases.Journal of the Saudi Heart Association · 2025Article
- Herpes Zoster and Cardiovascular Disease: Exploring Associations and Preventive Measures through Vaccination.Vaccines · 2024Review
- Knowledge, Attitudes and Practices Survey of Recombinant Zoster Vaccine among Cardiologists and Cardiac Nurses in Italy.Medicina (Kaunas, Lithuania) · 2024Article
- The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus.European respiratory review : an official journal of the European Respiratory Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myocardial infarction (MI) has been reported as a postinfection sequela of herpes zoster, but with limited data on incidence after zoster and protective effect of the zoster vaccine. This study investigates the risk of developing an MI 30 days postzoster, determines patient-specific risk factors, and investigates the impact of herpes zoster vaccination. Methods: This retrospective cohort study included patients who received care at a Veterans Affairs facility between 2015 and 2020. Time to MI was determined from either 30 days post-zoster infection (zoster cohort) or a primary care appointment (control cohort). Results: This study assessed a total of 2 165 584 patients. MI within 30 days occurred in 0.34% (n = 244) of the zoster cohort and 0.28% (n = 5782) of the control cohort ( Conclusions: Herpes zoster infection was associated with an increased risk of MI within the first 30 days postinfection. History of prior MI, male sex, age ≥50 years, history of heart failure, peripheral vascular disease, human immunodeficiency virus, prior cerebrovascular accident, and renal disease increased odds of MI 30 days postinfection with herpes zoster. Herpes zoster vaccination decreased the odds of developing an MI in patients aged ≥50 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.